Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Income from Non-Controlling Interests of -$1415.0 for Q1 2026, up 69.68% year-over-year from -$833.92 in Q1 2025, and up 85.97% quarter-over-quarter from -$10084.0 in Q4 2025.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Income from Non-Controlling Interests for 4 consecutive years, with -$1415.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 69.68% year-over-year to -$1415.0; the TTM figure through Mar 2026 stood at -$26257.0 (up 80.22% YoY), while the FY2025 annual figure was -$29509.0, up 87.8% from the prior year.
- Income from Non-Controlling Interests improved to -$1415.0 in Q1 2026 per EPRX's latest filing, from -$10084.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$1415.0 in Q1 2026 and bottomed at -$380394.0 in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged -$78314.4 across 4 years, with a median of -$47995.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests slumped 87.65% — and 2025, when it soared 95.9%.
- Eupraxia Pharmaceuticals' Income from Non-Controlling Interests stood at -$380394.0 in 2023, then surged by 93.85% to -$23385.0 in 2024, then jumped by 56.88% to -$10084.0 in 2025, then soared by 85.97% to -$1415.0 in 2026.
- Business Quant data shows EPRX's Income from Non-Controlling Interests at -$1415.0 in Q1 2026, -$10084.0 in Q4 2025, and -$7991.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 306.06 Mn | 306.06 Mn | - | -6,478.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,478.00 |
| Mar 31, 2026 | -1,415.00 |
| Dec 31, 2025 | -10,084.00 |
| Sep 30, 2025 | -7,991.00 |
| Jun 30, 2025 | -6,767.00 |
| Mar 31, 2025 | -4,667.00 |
| Dec 31, 2024 | -23,385.00 |
| Sep 30, 2024 | -47,995.00 |
| Jun 30, 2024 | -56,678.00 |
| Mar 31, 2024 | -113,895.00 |
| Dec 31, 2023 | -380,394.00 |
| Sep 30, 2023 | -174,741.00 |
| Jun 30, 2023 | -129,379.00 |
| Mar 31, 2023 | -60,696.00 |